Related Experiment Video

Updated: Jul 12, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Self-Cooperative RNA Vaccine Mitigates Dendritic Cell-Mediated Acquired Immune Resistance to Potentiate Cell Therapy

Lujia Huang1,2, Fangmin Chen1,2, Feng Zhou1,2

  • 1State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Advanced Materials (Deerfield Beach, Fla.)
|July 10, 2026
PubMed

Insights

New mRNA cancer vaccines overcome immune resistance by delivering RNA and PD-L1 inhibitors together. This self-cooperative RNA vaccine (SCORV) strategy enhances T-cell priming and boosts antitumor immunity.

Area of Science:

  • Immunology
  • Vaccinology
  • Nanotechnology

Background:

  • Conventional mRNA cancer vaccines can induce immune resistance, limiting their effectiveness.
  • Vaccination can upregulate programmed death-ligand 1 (PD-L1) on dendritic cells (DCs) via type I interferon (IFN-I) signaling.
  • Elevated PD-L1 impairs T-cell priming by engaging programmed death receptor 1 (PD-1) on T lymphocytes.

Purpose of the Study:

  • To identify and address vaccination-induced immune resistance mechanisms.
  • To develop an improved mRNA vaccine strategy that enhances antitumor immunity.
  • To create a self-cooperative RNA vaccine (SCORV) overcoming PD-L1-mediated immune suppression.

Main Methods:

  • Co-delivery of antigen-encoding RNA and small interfering RNA against PD-L1 (siPD-L1) within a single lipid nanoparticle (LNP).
  • Optimization of DC-targeted LNP formulation through screening of over 300 ionizable lipids.
  • Evaluation of SCORV efficacy in murine models of melanoma and hepatocellular carcinoma.

Main Results:

  • SCORV effectively suppresses PD-L1-mediated immune resistance during antigen presentation.
  • The strategy enhances T-cell priming and alleviates T-cell exhaustion.
  • SCORV potentiates tumor-infiltrating lymphocyte reactivity and elicits robust antitumor immunity.

Conclusions:

  • SCORV represents a rational design for mRNA vaccines that self-correct vaccination-induced immune resistance.
  • This approach offers a promising strategy for enhancing cancer vaccine efficacy.
  • The findings highlight the potential of combining immune checkpoint inhibition with mRNA vaccination.
Keywords:
RNA interferencelipid nanoparticlesmRNA cancer vaccinenegative immune regulationtumor‐infiltrating lymphocyte therapy

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...